dehydroepiandrosterone has been researched along with Female Genitourinary Diseases in 8 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The use of estrogen agonists/antagonists and intravaginal dehydroepiandrosterone (DHEA) have both been shown to positively affect vaginal atrophy symptoms without inducing endometrial proliferation." | 4.86 | Vulvovaginal atrophy: current and future therapies (CME). ( Ibe, C; Simon, JA, 2010) |
| " More recently, double-blind, placebo-controlled clinical trials have demonstrated that local vaginal dehydroepiandrosterone improves symptoms in postmenopausal women, including moderate to severe dyspareunia." | 3.88 | The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. ( Archer, DF; Bachmann, G; Davis, SR; Goldstein, AT; Goldstein, I; Kellogg-Spadt, S; Kim, NN; Lowenstein, L; Nappi, RE; Pinkerton, JV; Simon, JA; Stuenkel, CA; Traish, AM; Vignozzi, L, 2018) |
| "Ospemifene therapy was however superior to laser and vaginal estrogen therapies in ameliorating sexual function, however, it presents a high risk of developing adverse events and endometrial hyperplasia." | 2.72 | Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. ( Chang, Y; Duan, H; Li, B; Wang, S, 2021) |
| "Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM)." | 2.61 | Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. ( Abraham, J; Kruse, ML; Sussman, TA; Thacker, HL, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stute, P | 1 |
| Bertschy, S | 1 |
| Birkhaeuser, M | 1 |
| Bitzer, J | 1 |
| Ging, A | 1 |
| Raggi, A | 1 |
| Steimann, S | 1 |
| Stute, V | 1 |
| Holton, M | 1 |
| Thorne, C | 1 |
| Goldstein, AT | 2 |
| Smith, T | 1 |
| Sahni, S | 1 |
| Thacker, HL | 2 |
| Li, B | 1 |
| Duan, H | 1 |
| Chang, Y | 1 |
| Wang, S | 1 |
| Simon, JA | 2 |
| Goldstein, I | 1 |
| Kim, NN | 1 |
| Davis, SR | 1 |
| Kellogg-Spadt, S | 1 |
| Lowenstein, L | 1 |
| Pinkerton, JV | 1 |
| Stuenkel, CA | 1 |
| Traish, AM | 1 |
| Archer, DF | 1 |
| Bachmann, G | 1 |
| Nappi, RE | 1 |
| Vignozzi, L | 1 |
| Sussman, TA | 1 |
| Kruse, ML | 1 |
| Abraham, J | 1 |
| Vegunta, S | 1 |
| Files, J | 1 |
| Kling, JM | 1 |
| Ibe, C | 1 |
5 reviews available for dehydroepiandrosterone and Female Genitourinary Diseases
| Article | Year |
|---|---|
An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe | 2020 |
Postmenopausal Hormone Therapy-Local and Systemic: A Pharmacologic Perspective.
Topics: Dehydroepiandrosterone; Estrogen Replacement Therapy; Estrogens; Female; Female Urogenital Diseases; | 2020 |
Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
Topics: Bayes Theorem; Dehydroepiandrosterone; Estrogens; Female; Female Urogenital Diseases; Humans; Laser | 2021 |
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estrogens; Female; | 2019 |
Vulvovaginal atrophy: current and future therapies (CME).
Topics: Adjuvants, Immunologic; Aged; Atrophy; Dehydroepiandrosterone; Drug Administration Schedule; Drug Th | 2010 |
3 other studies available for dehydroepiandrosterone and Female Genitourinary Diseases
| Article | Year |
|---|---|
Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause.
Topics: Atrophy; Consensus; Dehydroepiandrosterone; Female; Female Urogenital Diseases; Humans; Menopause; S | 2022 |
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Topics: Administration, Intravaginal; Aged; Androgens; Atrophy; Consensus; Dehydroepiandrosterone; Dyspareun | 2018 |
Newer Name, Newer Treatments: The Genitourinary Syndrome of Menopause.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Estrogens; Fe | 2019 |